LLY

1,014.98

-0.96%↓

JNJ

240.9

+1.12%↑

ABBV

220.69

-0.72%↓

NVS

159.71

+1.01%↑

MRK

119.32

+1.9%↑

LLY

1,014.98

-0.96%↓

JNJ

240.9

+1.12%↑

ABBV

220.69

-0.72%↓

NVS

159.71

+1.01%↑

MRK

119.32

+1.9%↑

LLY

1,014.98

-0.96%↓

JNJ

240.9

+1.12%↑

ABBV

220.69

-0.72%↓

NVS

159.71

+1.01%↑

MRK

119.32

+1.9%↑

LLY

1,014.98

-0.96%↓

JNJ

240.9

+1.12%↑

ABBV

220.69

-0.72%↓

NVS

159.71

+1.01%↑

MRK

119.32

+1.9%↑

LLY

1,014.98

-0.96%↓

JNJ

240.9

+1.12%↑

ABBV

220.69

-0.72%↓

NVS

159.71

+1.01%↑

MRK

119.32

+1.9%↑

Search

Ligand Pharmaceuticals Inc

Atidarymo kaina

SektoriusSveikatos priežiūra

180.47 -1.11

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

178.73

Max

188.84

Pagrindiniai rodikliai

By Trading Economics

Pajamos

112M

117M

Pardavimai

115M

P/E

Sektoriaus vid.

81.987

121.746

Pelno marža

101.569

Darbuotojai

68

EBITDA

87M

149M

Rekomendacijos

By TipRanks

Rekomendacijos

Stiprus pirkimas

12 mėnesių prognozė

+26.89% upside

Dividendai

By Dow Jones

Kitas uždarbis

2026-02-26

Rinkos statistika

By TradingEconomics

Rinkos kapitalizacija

-440M

3.7B

Ankstesnė atidarymo kaina

181.58

Ankstesnė uždarymo kaina

180.47

Naujienos nuotaikos

By Acuity

20%

80%

29 / 352 reitingas Healthcare

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Strong Bearish Evidence

Ligand Pharmaceuticals Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-02-11 23:47; UTC

Karštos akcijos

Stocks to Watch: AppLovin, Cisco, Cognex, Pilgrim's Pride

2026-02-11 22:59; UTC

Uždarbis
Įsigijimai, susijungimai, perėmimai

Grab Holdings to Buy U.S.-Based Stash Financial

2026-02-11 23:54; UTC

Uždarbis

McDonald's Says Its Value Campaign Is Paying Off -- 2nd Update

2026-02-11 23:50; UTC

Rinkos pokalbiai

Global Equities Roundup: Market Talk

2026-02-11 23:50; UTC

Rinkos pokalbiai

Nikkei May Rise on Hopes for Takaichi's Economic Steps -- Market Talk

2026-02-11 23:49; UTC

Uždarbis

Singtel: Key Focus Areas Are Strengthening Core Businesses, Scaling Growth Engines, Building Momentum Across Regional Associates >Z74.SG

2026-02-11 23:45; UTC

Uždarbis

Singtel: Net Exceptional Gain of S$1.15B in 3Q Primarily From Sale of Partial Stake in Bharti Airtel>Z74.SG

2026-02-11 23:42; UTC

Uždarbis

Singtel 3Q Underlying Net Profit S$744M Vs. S$680M >Z74.SG

2026-02-11 23:41; UTC

Uždarbis

Singtel 3Q Net S$1.89B Vs. Net S$1.32B >Z74.SG

2026-02-11 23:40; UTC

Uždarbis

Singtel 3Q Operating Revenue S$3.66B Vs. S$3.63B >Z74.SG

2026-02-11 23:35; UTC

Rinkos pokalbiai

Gold Falls on Prospects of Long Fed Pause -- Market Talk

2026-02-11 23:18; UTC

Rinkos pokalbiai

AppLovin CEO Looks to Soothe Concerns Over AI, Competition -- Market Talk

2026-02-11 23:14; UTC

Rinkos pokalbiai

RBA Governor Faces Barrage of Questions About Govt Spending -- Market Talk

2026-02-11 22:59; UTC

Uždarbis

Kakao 2025 Net KRW525.72B Vs. Loss KRW161.87B >035720.SE

2026-02-11 22:59; UTC

Uždarbis

Kakao 2025 Oper Pft KRW732.04B Vs. Pft KRW460.21B >035720.SE

2026-02-11 22:59; UTC

Uždarbis

Kakao 2025 Rev KRW8.099T Vs. KRW7.872T >035720.SE

2026-02-11 22:58; UTC

Uždarbis

Kakao 4Q Net Loss Missed FactSet-Compiled Consensus

2026-02-11 22:57; UTC

Uždarbis

Kakao 4Q Loss KRW39.30B Vs. Loss KRW395.21B >035720.SE

2026-02-11 22:54; UTC

Uždarbis

Kakao 4Q Oper Pft KRW203.45B Vs. Pft KRW75.43B >035720.SE

2026-02-11 22:53; UTC

Uždarbis

Kakao 4Q Rev KRW2.133T Vs. KRW1.957T >035720.SE

2026-02-11 22:47; UTC

Uždarbis

AppLovin Reports Strong Earnings. The Stock Is Down. -- Barrons.com

2026-02-11 22:47; UTC

Uždarbis

AppLovin Reports Strong Earnings. The Stock Is Down. -- Barrons.com

2026-02-11 22:23; UTC

Uždarbis

Grab Holdings Expects to Close Stash Acquisition in 3Q of 2026 >GRAB

2026-02-11 22:22; UTC

Uždarbis

Grab Holdings to Acquire U.S. Digital Financial Services Company Stash Financial >GRAB

2026-02-11 22:22; UTC

Uždarbis

Grab Holdings Sees FY26 Adj Ebitda $700M to $720M >GRAB

2026-02-11 22:19; UTC

Uždarbis

Grab Holdings Sees FY26 Rev $4.04B to $4.10B >GRAB

2026-02-11 22:18; UTC

Uždarbis

Grab Holdings 4Q Adj Ebitda $148.0M Vs. $97.0M >GRAB

2026-02-11 22:18; UTC

Uždarbis

Grab Holdings 4Q Net $153.0M Vs. Net $11.0M >GRAB

2026-02-11 22:18; UTC

Uždarbis

Grab Holdings 4Q Oper Pft $52.0M Vs. $2.0M >GRAB

2026-02-11 22:16; UTC

Uždarbis

Grab Holdings 4Q Rev $906.0M Vs. $764.0M >GRAB

Akcijų palyginimas

Kainos pokytis

Ligand Pharmaceuticals Inc Prognozė

Kainos tikslas

By TipRanks

26.89% į viršų

12 mėnesių prognozė

Vidutinis 237.2 USD  26.89%

Aukščiausias 270 USD

Žemiausias 220 USD

Remiantis 6 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Ligand Pharmaceuticals Inc kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Stiprus pirkimas

6 ratings

6

Pirkti

0

Laikyti

0

Parduoti

Techninis įvertinimas

By Trading Central

102.5 / 109.24Palaikymas ir pasipriešinimas

Trumpalaikis periodas

Strong Bearish Evidence

Vidutinės trukmės periodas

Very Strong Bearish Evidence

Ilgalaikis periodas

Weak Bullish Evidence

Rinkos nuotaikos

By Acuity

29 / 352 reitingas Sveikatos priežiūra

Naujienos nuotaikos

Labai stiprus bulių rinkos įrodymas

Svyravimai

Žemiau vidurkio

Naujienų apimtis (RCV)

Žemiau vidurkio

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

$

Apie bendrovę Ligand Pharmaceuticals Inc

Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, engages in the development and licensing of biopharmaceutical assets worldwide. Its commercial programs include Kyprolis and Evomela, which are used to treat multiple myeloma; Rylaze, a recombinant erwinia asparaginase for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma in adult and pediatric patients; Filspari, a dual endothelin and angiotensin II receptor antagonist in development for rare kidney diseases and non-immunosuppressive treatment indicated for immunoglobulin A nephropathy; Teriparatide injection product for osteoporosis; Vaxneuvance for the prevention of invasive disease caused by streptococcus pneumoniae serotypes; and Pneumosil, a pneumococcal conjugate vaccine to help fight against pneumococcal pneumonia among children. The company also offers TZIELD, a CD3-directed antibody indicated to delay the onset of Stage 3 type 1 diabetes (T1D) in adults and children aged 8 years and older with Stage 2 T1D; Nexterone, a captisol-enabled formulation of amiodarone; Zulresso, a captisol-enabled formulation of brexanolone for the treatment of postpartum depression; and Veklury, an antiviral treatment for moderate or severe COVID-19. In addition, it provides Noxafil-IV, a captisol-enabled formulation of posaconazole for IV use; Duavee for the treatment of post-menopausal symptoms in women; Exemptia for autoimmune diseases; Vivitra for breast cancer; and Bryxta and Zybev for various indications. The company has alliances, licenses, and other business relationships with Amgen, Merck, Pfizer, Jazz, Takeda, Gilead Sciences, and Baxter International. Further, it sells Captisol materials. Ligand Pharmaceuticals Incorporated was incorporated in 1987 and is based in Jupiter, Florida.
help-icon Live chat